Ascletis announced today it has successfully completed <span class="xn-money">US$100 million</span> (<span class="xn-money">RMB 700 million</span>) series B financing. The investment was led by C-Bridge Capital, joined by a number of new investors including QianHai Equity Investment FOF, FOCUS Media Jiangnanchun Foundation, WTT Investment, together with the current investors Goldman Sachs, Tasly Pharmaceutical which participated in series A financing. Ascletis plans to use the proceeds from this financing to expand its product portfolio and sales force.